At New Day Diagnostics, we create tests that are accurate, easy to use and affordable.
In doing so, we empower people to manage their health on their terms while helping health systems enhance the care they deliver with efficient and accurate tools.
Our commitment is to bring innovative solutions to the healthcare market that improve health outcomes for people around the world.
We passionately serve and collaborate with healthcare professionals, the scientific community and consumers alike by providing accurate, fast and easy-to-use diagnostic tests that enable the early detection of a broad spectrum of diseases.
Important New Tests/Products in Development
Whether it’s at home or in a professional healthcare setting, the benefits of fast, easy, accurate diagnostics aren’t limited to one disease.
That’s why New Day Diagnostics is constantly innovating and adding to our line of testing products:
Celiac disease is a serious lifelong gastrointestinal disorder that can cause a wide spectrum of disruptive symptoms. However, 83% of celiac disease cases are undiagnosed. Our proprietary BIOCARD® Celiac Disease Self-Test uses a blood sample from a finger prick to identify the antibodies associated with celiac disease, allowing patients to mitigate symptoms by shifting to a gluten-free diet.1 Currently available in Europe. Clinical studies in progress for FDA approval.
Three common illnesses – COVID-19, Influenza, and RSV – share similar symptoms, which makes correct diagnosis essential to treatment. Our Multiplex BIOCARD® SARS-CoV-2 + Flu A + Flu B + RSV test uses one simple nasal swab and combo test card to identify which disease is present, so patients and providers can make the best care decisions. Status? Clinical studies in progress for FDA approval.
Helicobacter pylori (H. pylori) bacteria can cause stomach infections and ulcers, with symptoms including heartburn and digestive issues. While an infection can be treated with antibiotics, most cases go undiagnosed. Our BIOCARD® Helicobacter pylori IgG Test offers high accuracy and easy detection in just 10 minutes using a single drop of blood. Importantly, antacid medication or antibiotics do not interfere with test results, so patient comfort can be maintained.1 Currently available in Europe. Clinical studies in progress for FDA approval.
Ovarian cancer is the deadliest reproductive cancer and is difficult to detect, particularly at early stages. Our test, Ovation, showed higher accuracy and specificity compared to the most commonly used test, which we hope will allow earlier diagnosis and improve the chance of survival for patients. In development.
Prostate cancer is the most frequent cause of cancer in men. However, current diagnostic testing performs poorly in the early stages of the disease, resulting in needless biopsies and higher healthcare costs. Our non-invasive ProCare test leverages a novel biomarker for the detection of prostate cancer, hopefully allowing for earlier and more effective treatment. In development.
H. Pylori produces urease that hydrolyses urea to ammonia and raises the pH of the medium, changing the color of the medium. The BIOCARD® or Helicobacter pylori Urease Test is an easy tablet test for the rapid detection of the urease activity of biopsy and culture samples.
The tablet is added into water together with the biopsy or culture sample and a positive reaction can mostly be seen within 20-30 minutes. Sensitivity of 95% and specificity 98.3 % exceeds competitive offerings.1 Currently available in Europe. Clinical studies in progress for FDA approval.